T3D Therapeutics’ mission is to develop its lead drug product candidate, T3D-959, as a potential ‘First-in-Class’ and ‘Best-in-Class’ disease-modifying, breakthrough medicine for the treatment of Alzheimer’s disease with the potential to slow, stop or reverse the course of the disease.

Pharmaceutical

T3D Therapeutics

T3D Therapeutics' headquarters in Durham, NC, United States

The Advisory and Consulting team at T3D Therapeutics provides expert guidance and strategic advice on the development and clinical testing of T3D-959. Leveraging their extensive industry knowledge, they support the company in regulatory affairs, market positioning, and optimizing treatment protocols to advance T3D-959 as a leading therapy for Alzheimer's disease.

Advisory and Consulting

The Leadership Team at T3D Therapeutics is responsible for steering the company's strategic direction, overseeing the development of T3D-959, and ensuring alignment between scientific research and clinical objectives. Comprising top executives with expertise in science and medicine, they drive innovation and decision-making to advance breakthrough therapies for Alzheimer's disease.

��

People (9)

Jobs (0)

Other teams

Leadership Team

��������

People (9)

Jobs (0)

Other teams

Leadership Team

��